Back to Home

VBC Market Dynamics

Expert articles and analysis related to vbc market dynamics.

200 articles•Last 30 Days

AI Summary — Last 30 Days

VBC market activity is concentrating around two pressure points: Medicare Advantage payment integrity and risk adjustment volatility, and Medicaid affordability for high-cost therapies. MA plans are aggressively contesting CMS’ 2027 Star Ratings methodology—Aetna says more than $2B is at stake and Centene estimates a $448M hit—while KFF data show 4.3M beneficiaries face MA or Part D plan terminations at the end of 2026, signaling continued benefit redesign, market exits, and network disruption for providers tied to MA value-based contracts (Aetna lawsuit; KFF plan terminations). At the same time, Privia’s $36M acquisition of American Choice Healthcare’s MSSP business points to continued consolidation around ACO infrastructure, while Health Affairs’ focus on GLP-1 access under the BALANCE Model and social risk adjustment underscores a broader shift: VBC stakeholders are pushing for payment models that can absorb expensive therapeutics and account for patient complexity without penalizing providers serving higher-risk populations.

Related Articles

95ALN

OKC's largest private employer Integris set to join Kaiser-backed Risant

OKC's largest private employer Integris set to join Kaiser-backed Risant  The Oklahoman

The OklahomanOct 21, 2026
95ALN

AHA urges court to reject drug industry intervention in 340B rebate program case

AHA urges court to reject drug industry intervention in 340B rebate program case  American Hospital Association

AHAOct 21, 2026
95ALN

INTEGRIS Health in Oklahoma to be acquired by Risant Health under new agreement

INTEGRIS Health in Oklahoma to be acquired by Risant Health under new agreement  KOKH

KOKHOct 21, 2026
95ALN

Integris Health to Become Third Health System to Join Kaiser-Backed Risant Health

Integris Health to Become Third Health System to Join Kaiser-Backed Risant Health  HCI Innovation Group

Healthcare InnovationOct 21, 2026
95ALN

Price of new drugs up 35% since 2022: 6 things hospital leaders should know

Price of new drugs up 35% since 2022: 6 things hospital leaders should know  Becker's Hospital Review

Becker's Hospital ReviewOct 21, 2026
95ALN

The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It.

The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It.  AcademyHealth

AcademyHealthOct 21, 2026
95ALN

INTEGRIS Health set to join Kaiser Permanente subsidiary Risant Health

INTEGRIS Health set to join Kaiser Permanente subsidiary Risant Health  KFOR

KFOROct 21, 2026
95ALN

Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025

Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025  American Hospital Association

AHAOct 20, 2026
95ALN

New ICER report suggests drug launch prices are outpacing their worth

The median list price of drugs at launch rose 24% from 2022 to 2025, and the net prices of those drugs rose even higher, according to a new report from the Institute for Clinical and ...

Endpoints NewsOct 20, 2026
95ALN

STAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis finds

The median net price for 202 newly launched medicines rose by 35%, to $257,000 last year from $173,000 in 2022.

STAT NewsOct 20, 2026